A Phase 1b/2 Study of PCM-075 in Combination With Either Low-Dose Cytarabine or Decitabine in Subjects With Acute Myeloid Leukemia (AML)

Trial Profile

A Phase 1b/2 Study of PCM-075 in Combination With Either Low-Dose Cytarabine or Decitabine in Subjects With Acute Myeloid Leukemia (AML)

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Cytarabine (Primary) ; Decitabine (Primary) ; PCM 075 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors TrovaGene
  • Most Recent Events

    • 09 Oct 2017 According to a TrovaGene media release, this study was accepted by the National Library of Medicine (NLM).
    • 02 Oct 2017 Planned number of patients changed from 60 to 116.
    • 02 Oct 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top